Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has become the first drug to be approved by the US Food and Drug Administration (FDA) as a treatment for noncirrhotic nonalcoholic ...

This shift toward noninvasive testing options could significantly impact patient awareness and management of NASH, aligning with long-term goals to improve disease diagnosis and treatment ...

Researchers at Georgetown University have developed a new drug called CTPI-2, which targets a key gene known as Slc25a1. This ...

ACLY inhibitors also show potential in NASH treatment. Sino Biological provides recombinant NASH-related drug targets to support drug discovery and study the interactions between these targets ...

He believes that NASH treatment is destined to progress rapidly towards combination treatment, just as hep C has, and that these doctors “wrote the book” on how to combine two unapproved ...

Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC” ...

Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic ...

This might imply that NASH is the shared end result of varying ... If this hypothesis is true, we should try to tailor treatment to each subject. We hypothesized that analysis of morphological ...